The Opening Ceremony of Cangzhou GMP Production Base

On the morning of April 1, 2023, the Opening Ceremony of Laviana Pharma’s Cangzhou GMP Production Base was held. Mr. Chen Wenting (Chairman of Laviana Pharma), Dr. Cheng Chao (Executive Director, Co-President and COO of Laviana Pharma), Mr. Shi Jianjie (Senior Partner and CRO of Yingke PE), Dr. Li Zhibin (Deputy General Manager of Shenzhen Chipscreen Biosciences Co., Ltd.), Dr. Chai Bing (Head of R&D, Shanghai Hutchison Pharmaceuticals), Dr. Qian Hao (General Manager of Laviana Pharma (Cangzhou) Co., Ltd.) as well as investors, partners, media and industry experts attended the ceremony.

Mr. Chen Wenting, Chairman of Laviana Pharma, dotted the eyes of the Dancing Lion.

Laviana Pharma is a dynamic pharmaceutical contract development and manufacturing organization (CDMO) that has been at the forefront of innovation since its founding in 2003. Our technology-driven approach enables us to provide a comprehensive suite of services that spans the entire drug development lifecycle, from laboratory to commercialization.

At Laviana Pharma, we specialize in Chemistry, Manufacturing, and Controls (CMC) for small molecule innovative drugs. Our team of experts is equipped to handle every aspect of the process, including process study, pliot production, and commercial production for APIs, regulatory starting materials, and pharmaceutical intermediates. We support our clients throughout the entire journey from pre-clinical to marketing, providing submission for approval during the development process. Choose Laviana Pharma for cutting-edge solutions that bring your innovative drug to life.

Lion Dance Performance at the Opening Ceremony of Cangzhou GMP Production Base

In 2015, Laviana Pharma completed its shareholding system reform and has since expanded into a network of four subsidiaries: Laviana Pharma (Jiangsu) Co., Ltd. - Pilot plant, Laviana Pharma (Tianjin) Co., Ltd. - our R&D and Innovation Center, Laviana Pharma (Cangzhou) Co., Ltd. - our GMP production base for advanced intermediates and APIs, and Laviana Pharma (Anhui) Co., Ltd. - our R&D Engineering Center and GMP production base for APIs and intermediates. Additionally, Laviana Pharma has established several business centers worldwide, including our Beijing and Shanghai offices in China, our California office in the U.S., our Singapore office in Southeast Asia, and our France office in Europe. Our global presence is a testament to our commitment to developing both domestic and international business simultaneously. Over the past two decades, Laviana Pharma has successfully completed thousands of process development projects, including nearly 100 pilot and production projects for innovative drug RSM and intermediates. We are proud of our achievements and look forward to continuing to push the boundaries of pharmaceutical innovation.

Ribbon-cutting Ceremony for Completion of Cangzhou GMP Production Base

Cangzhou GMP Production Base, located in Cangzhou Lingang Economic and Technological Development Zone, Hebei Province, is intended to be used as the GMP production base for advanced intermediates and APIs. It costs a total of RMB 400 million and covers a total area of 66,000 m2. The Phase I project of production base consists of a high-pressure hydrogenation production line and a workshop with 12 independent production lines. Among them, 2 production lines can be used as special production lines for OEB4 projects, which are equipped with 200L-6,300L reactors made of glass-lined, stainless steel and Hastelloy materials, as well as major process equipments such as horizontal centrifuges, three-in-one devices, enabling the company to undertake CDMO business for various types of small molecule compounds.

Dr. Cheng Chao, Executive Director and Co-President of Laviana Pharma

During her speech, Dr. Cheng Chao, Executive Director and Co-President of Laviana Pharma, highlighted the company's unwavering commitment to the development and production of small molecule drugs. Over the years, Laviana Pharma has continuously delivered high-quality services to more than 300 well-known pharmaceutical customers in China and abroad. The completion and running of the Cangzhou GMP Production Base represent an important milestone in Laviana Pharma's development. The new facility will further enhance our CDMO one-stop integrated service platform, enabling us to provide even more comprehensive pharmacy services to our clients. Looking ahead, Laviana Pharma remains steadfast in our corporate values of "People-oriented, Science-driven, Active cooperation, Customer First and Pursuit of Excellence." We will continue to invest in R&D and production capacity, accelerate the development of global pharmaceutical innovation, and push the boundaries of what's possible in the world of small molecule drugs.

Mr. Shi Jianjie, Senior Partner of Yingke PE

Mr. Shi Jianjie, Senior Partner and CRO of Yingke PE, said in his speech that the CDMO industry is currently in continuous mass growth and maintains a high market prosperity. At present, Laviana Pharma is transforming rapidly from CDO to CDMO. As commercial plants are the key to corporate transformation, Cangzhou Production Base is intended to be used as GMP production base for advanced intermediates and APIs. We are looking forward to the listing of Laviana Pharma in the near future, to grow bigger and stronger, and to create more successes!

Dr. Li Zhibin, Deputy General Manager of Shenzhen Chipscreen Biosciences Co., Ltd.

Dr. Li Zhibin, Deputy General Manager of Shenzhen Chipscreen Biosciences Co., Ltd., said that Laviana Pharma has been working with Chipscreen Biosciences for more than a decade and supporting the production of all new drugs of Chipscreen Biosciences. The establishment of Cangzhou GMP Production Base will create more space for the long-term cooperation between Laviana Pharma and Chipscreen Biosciences as well as other partners. In the future, both parties will continue to strengthen cooperation and develop more and better affordable innovative drugs for the public.

Dr. Chai Bing, Shanghai Hutchison Pharmaceuticals

Dr. Chai Bing, Head of R&D, Shanghai Hutchison Pharmaceuticals, said that Laviana Pharma achieved rapid development in recent years, from the commencement of Cangzhou GMP Production Base in 2019, through the compeltion of Series C financing in 2021, the start of the New Drug & API Production and R&D Industrial Park Project, the completion of Series C+ financing in 2022, to the official completion of Cangzhou GMP Production Base today. He believes that Laviana Pharma will definitely grow stronger and develop into a vigorous and creative company thanks to the joint efforts of Group leaders and employees.

Dr. Qian Hao, General Manager of Laviana Pharma (Cangzhou) Co., Ltd.

“The completion and running of Cangzhou GMP Production Base is not only a major milestone of Laviana Pharma in its 20 years of development, but also a practical action of Laviana Pharma to explore and extend the value chain of CDMO, enabling the whole process service for process development and production of small molecule innovative drugs. In the future, we will develop into a model for plants with full CDMO services at home and abroad with outstanding teams, excellent management, attractive services and a high-quality, flagship CDMO plant.” said Dr. Qian Hao, General Manager of Laviana Pharma (Cangzhou) Co., Ltd.

Partial Aerial View of Laviana Pharma (Cangzhou) Co., Ltd.

The completion of Laviana Pharma’s Cangzhou GMP Production Base marks a more steady and solid development of Laviana Pharma in the pharmaceutical industry. In the future, Laviana Pharma will uphold the corporate mission of “changing the world with art of chemistry”, strictly abide by production safety codes and pharmaceutical regulations, actively explore and extend downstream of the industry value chain, strive to become a flagship CDMO company, and provide more one-stop comprehensive services for domestic and foreign innovative pharmaceutical companies, accelerating global pharmaceutical innovation.